James William Galasso Iii, DO | |
1200 Main St, Swoyersville, PA 18704-1318 | |
(570) 283-3301 | |
(570) 283-3304 |
Full Name | James William Galasso Iii |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 33 Years |
Location | 1200 Main St, Swoyersville, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376579300 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | OS007884L (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Comprehensive Medical Home Care | Dupont, PA | Home health agency |
Commonwealth Home Health & Hospice Of Wilkes-barre | Forty fort, PA | Home health agency |
Bayada Home Health Care, Inc. | Pittston, PA | Home health agency |
Wilkes-barre General Hospital | Wilkes-barre, PA | Hospital |
Geisinger Wyoming Valley Medical Center | Wilkes barre, PA | Hospital |
Mailing Address | Practice Location Address |
---|---|
James William Galasso Iii, DO 1200 Main St, Swoyersville, PA 18704-1318 Ph: (570) 283-3301 | James William Galasso Iii, DO 1200 Main St, Swoyersville, PA 18704-1318 Ph: (570) 283-3301 |
News Archive
Telesta Therapeutics Inc. announced today that it has closed a private placement financing of US$28.6 million. This transaction was led by several prominent U.S. healthcare investors, including Consonance Capital Investors, Boxer Capital of Tavistock Life Sciences and Omega Funds. In addition, certain members of the senior management team and board of directors of Telesta participated in the transaction.
Taconic, a leading provider of life sciences solutions, and Oncodesign(R), an innovative leader in the discovery of novel anti-cancer therapies, announce today that they have entered into an agreement to co-develop and co-promote pre-clinical oncology in vivo solutions for researchers worldwide. The agreement provides researchers with improved access to a large, diverse portfolio of translational models for use in pre-clinical oncology studies, along with supporting scientific services.
Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.
BioNano Genomics announced today a $10 million financing to support the ongoing development and commercialization of the IrysTM System for human genome analysis. Current investors, Battelle Ventures, Domain Associates, Gund Investment Corporation, participated in the financing.
Today, Lung Cancer Alliance announced that its efforts to secure increased federal research funding for lung cancer achieved another victory as an additional $12.8 million was included in the Department of Defense Congressionally Directed Medical Research Program which was part of the FY2011 budget compromise approved by Congress.
› Verified 2 days ago